The Prognostic and Immune Significance of BZW2 in Pan-Cancer and its Relationship with Proliferation and Apoptosis of Cervical Cancer

Chaolin Li¹,†, Qin Li¹,†, Li Li¹, Siyu Sun¹, Xun Lei¹,*

¹Jinniu Maternity and Child Health Hospital of Chengdu, 610000 Chengdu, Sichuan, China
*Correspondence: JNFY_leixun@163.com (Xun Lei)
†These authors contributed equally.

Abstract

Background: Basic leucine zipper and W2 domains 2 (BZW2), a member of the basic domain leucine zipper superfamily of transcription factors, has been implicated in the development and progression of various cancers. However, the precise biological role of BZW2 in pan-cancer datasets remains to be explored. This study aimed to assess the prognostic significance of BZW2 and its immune-related signatures in various tumors. Methods: Our study investigated the expression, epigenetic modifications, and clinical prognostic relevance of BZW2 using multi-omics data in different cancer types. Additionally, the immunological characteristics, tumor stemness, drug sensitivity, and correlation of BZW2 with immunotherapy response were explored. Finally, in vitro experiments were conducted to assess the impact of BZW2 knockdown on Hela cells, a cell line derived from cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC).

Results: BZW2 exhibited elevated expression levels in various tumor tissues and significantly impacted the prognosis of different cancer types. BZW2 emerged as an independent prognostic factor in CESC. We found that copy number amplification and methylation levels of BZW2 were associated with its mRNA expression. Immunological analyses revealed that BZW2 shapes a non-inflamed immunosuppressive tumor microenvironment across multiple cancers. Furthermore, our cell experiments demonstrated that BZW2 knockdown reduced proliferation, migration, and apoptosis activities in CESC cells. Conclusions: BZW2 promotes cancer progression by shaping a non-inflamed immunosuppressive tumor microenvironment. Additionally, BZW2 was shown to significantly influence the proliferation, migration, and apoptosis of CESC cells.

Keywords: BZW2; CESC; immunity therapy; apoptosis; biomarkers

1. Introduction

Cancer remains a substantial global health challenge, imposing significant burdens on public health systems worldwide [1]. According to projections made by the American Cancer Society, there will be around 1.91 million new instances of cancer in the US in 2022, with 600,000 cancer-related deaths expected as a result [2]. The impact of cancer is particularly pronounced in China, with an estimated 4.82 million new cancer cases and 3.21 million cancer-related deaths in the same year [3]. Consequently, cancer has become an urgent issue, requiring immediate attention. The advent of immunotherapy has instilled hope in patients with cancer, with notable advancements in the development of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies [4,5]. These treatments have demonstrated significant effectiveness in the management of various malignant tumors, including melanoma [6], non-small cell lung cancer [7], and non-Hodgkin lymphoma [8]. However, the limited applicability of immunotherapy due to its specificity poses a significant challenge [9]. Consequently, there is an imminent need to uncover the specific immunological signatures associated with different cancer types and identify new targets that can be effectively utilized in immunotherapy. Moreover, there is an urgent requirement to actively seek alternative therapeutic targets and novel tumor biomarkers to enhance cancer diagnosis and treatment.

Basic leucine zipper and W2 domains 2 (BZW2) belongs to the basic leucine zipper (bZIP) superfamily of transcription factors [10]. Initially considered a novel protein interacting with E-cadherin, BZW2 has been associated with multiple processes in cancer [11]. Wu et al. [12] were the first to employ a combined analysis of mouse and human microarray data, along with chromatin immunoprecipitation, to identify genes closely associated with c-MYC-induced tumors. Their findings indicated the involvement of BZW2 in tumorigenesis. Jin et al. [13] further demonstrated that BZW2 promotes the progression of hepatocellular carcinoma (HCC) by modulating the PI3K/AKT/mTOR signaling pathway. Li et al. [14] clarified the process by which BZW2 mediates c-Myc expression, acting as an oncogene in the development of HCC. A recent study also showed that high BZW2 expression affects the immune response of pancreatic adenocarcinoma (PAAD) and is an independent predictor of poor prognosis of PAAD [15]. These results imply that BZW2 may be a useful predictive biomarker and a possible target for treatment. However, despite our current understanding of the mechanisms
2. Materials and Method

2.1 Datasets Acquisition

The Gene Expression Omnibus (GEO) database was used to retrieve four cancer-related datasets, including GSE9750 for cervical cancer, GSE19804 for lung cancer, GSE17025 for endometrial cancer, and GSE43837 for breast cancer.

The University of California Santa Cruz (UCSC) Xena website (https://xenabrowser.net/datapages/) provided the mRNA normalized expression profiles, phenotype data, normal tissues in the Genotype-Tissue Expression (GTEx) database, DNA methylation profiles, and copy number variations (CNV) data for 33 different cancer types. The Cancer Cell Line Encyclopedia (CCLE, https://sites.broadinstitute.org/ccle) was used to download data on cell line expression. Genomic Data Commons (GDC) (https://portal.gdc.cancer.gov/) provided the level 4 simple nucleotide variation (SNV) dataset for all The Cancer Genome Atlas (TCGA) samples processed using MuTect2 software (version 4.1.0.0, illumine, Inc., San Diego, CA, USA) [16]. The mRNA expression profiles of immune cells were obtained from both the Human Protein Atlas (HPA) database (https://www.proteinatlas.org/) and the study by Monaco et al. [17]. Data on microsatellite instability (MSI) and tumor mutation burden (TMB) for 33 different cancer types were gathered from research by Thorsson et al. [18] and Bonniveille et al. [19], respectively. Data on the infiltration of pan-cancer immune cells were gathered from the Tumor Immune Estimation Resource 2.0 (TIMER2.0, http://timer.cistrome.org/). The Tracking Tumor Immunophenotype metasterver (http://biocc.hrbmu.edu.cn/TIP/index.jsp) was used to download immune activity ratings. The source of The Cancer Immunome Atlas (TCIA, https://tcia.at/home) provided the immunophenoscore (IPS). Furthermore, for association analysis with BZW2 expression, each tumor’s epigenetically regulated RNA expression-based (EREG.EXPss) and RNA expression-based (RNAss) tumor stemness scores were used from earlier work [20].

2.2 Analysis of Immune Signatures, Stemness Scores, and Drug Sensitivity of BZW2 in Pan-Cancer

Our study utilized the method developed by Zeng et al. [21] to examine the correlation between BZW2 and the tumor microenvironment in a cohort of 33 tumors. The Stro-malScore, ImmuneScore, and ESTIMATEScore of tumor samples were computed using the R program ESTIMATE, and their connection with BZW2 was evaluated [22]. BZW2 and immune cell infiltration were compared in several cancer types using single sample gene set enrichment analysis (ssGSEA) and xCell methods [23,24]. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and IPS from the TCIA database were utilized to evaluate the immunotherapy response. To compute the stemness index and evaluate its relationship with BZW2 expression, Malta et al.’s [20] one-class logistic regression machine learning algorithm (OCLR) was employed. Based on the “oncoPre-dict” package, the relationship between BZW2 and the IC50 of medicines from the Genomics Database of Cancer Drug Sensitivity V2 (GDSC V2, https://www.cancerrxgene.org/) was assessed [25,26].

2.3 Gene Set Variation Analysis (GSVA) and Correlation Analysis

Using transcriptome data from TCGA, GSVA enrichment analysis was carried out to assess the biological role of BZW2 in cancers. 50 pathway gene sets were analyzed for enrichment in each pan-cancer sample based on the HALLMARK pathway set from the Molecular Signatures Database (https://www.gsea-msigdb.org/gsea/index.jsp). The Spearman correlation between BZW2 and each HALLMARK pathway is then determined. Furthermore, pathways associated with immune inflammation were retrieved from the Kyoto Encyclopedia of Genes and Genomes (KEGG) official website (https://www.kegg.jp/). Immune-inflammation-related pathway scores were calculated using the ssGSEA method, and their relationship to BZW2 was evaluated.

2.4 Clinical Prognostic Value of BZW2 in Pan-Cancer

To assess the clinical prediction value of BZW2, survival data for pan-cancer, such as overall survival (OS), progression-free interval (PFI), disease-free interval (DFI), and disease-specific survival (DSS), were obtained from the TCGA database. The BZW2 high expression and low expression groups comprised all patients of each cancer type, according to the best cutoff value. To examine the relationship between BZW2 expression and patient prognosis, Cox analysis and Kaplan-Meier (KM) survival curves were produced using the R packages “survival” and “survminer” and then analyzed. To examine the prediction accuracy of the BZW2, TimeROC (receiver operating characteristic) study was used. In order to find independent predictive indicators, univariable and multivariable Cox regression analyses were undertaken.

and functions of BZW2 in certain cancers, a comprehensive evaluation of its prognosis, epigenetic changes, and immunological characteristics across diverse cancer types is lacking. Therefore, in this study, we comprehensively analyzed BZW2 expression and prognostic epigenetic changes across various cancer types. Additionally, we evaluated the immunological characteristics of BZW2 in pan-cancer and its correlation with immunotherapy response and performed cell experiments to verify its potential role in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). Our study aims to enhance our understanding of BZW2 immune signatures in tumors and provide new insights into immunotherapy.

...
2.5 Cell Culture, RNA Extraction, and Quantitative Real-Time PCR (qRT-PCR)

Hela cells were obtained from the Chinese Academy of Sciences’ Cell Bank in Shanghai, China. The cells were grown in DMEM medium (HyClone, Inc., Logan, UT, USA) containing 10% fetal bovine serum (Vazyme biotech co., Nanjing, Jiangsu, China), 100 mg/mL streptomycin and 100 U/mL penicillin. Cells were incubated in a humidified atmosphere with 5% CO₂ at 37 °C. Total RNA was isolated using the TRIzol reagent (Invitrogen, Inc., Carlsbad, CA, USA), as directed by the manufacturer. 1 µg of RNA was used for cDNA synthesis by the Hiscipt III 1st strand cDNA synthesis kit (Vazyme biotech co., Nanjing, China). GAPDH was amplified from each sample to ensure equal cDNA input. Each PCR reaction contained 1 µL of cDNA, 0.6 µL of forward and reverse primers (10 µM), 7.5 µL of ChamQ Universal SYBR qPCR Master Mix (Vazyme biotech co., Nanjing, China), and 6.3 µL of ddH₂O. The PCR reaction parameters were as follows: 10 minutes of pre-denaturation at 95 °C, 40 cycles of denaturation for 15 seconds at 95 °C, 1 minute of annealing at 62 °C, and 15 seconds of extension at 72 °C. A reaction was required at 60 °C for one minute and 95 °C for fifteen seconds in the last extension phase. The forward and reverse primers for GAPDH were GGAGCGAGAGTCCCTCCAAAAT and GGCTGTTGTCATACTTCATGG, respectively. The forward and reverse primers for BZW2 were CCAGTCTCTTCACCGACAGCTT and GACCGAGGAAGCTGTTGTGGCATC, respectively. The Hela cells line were validated by short tandem repeat profiling and tested negative for mycoplasma.

2.6 Western Blotting

Cells were harvested following treatment with siRNAs. The cells were then collected by centrifugation after being cleaned three times with phosphate-buffered saline (PBS). Proteinase inhibitors (#R0010, Solarbio, Inc., Beijing, China) were added to RIPA buffer to help create total protein extracts. BZW2 (#ab254772, Abcam, Inc., Shanghai, China) and GAPDH (#60004-1-Ig, Proteintech Group, Inc., Wuhan, China) antibodies were used in line with the manufacturer’s instructions for western blot analysis. Goat Anti-Mouse IgG-HRP (#SA00001-1, Proteintech Group, Inc., Wuhan, China) and Goat Anti-Rabbit IgG-HRP (#SA00001-2, Proteintech Group, Inc., Wuhan, China) were the secondary antibodies used. The protein loading control was GAPDH. The enhanced chemiluminescence (ECL) reagent (Beijing 4A Biotech Co., Ltd., Beijing, China) was used to visualize the signals.

2.7 Counting Kit-8 (CCK8) Detection and Transwell Migration Assay

Hela cells transfected with siRNAs-BZW2 were harvested upon reaching 90% confluency. They were then seeded onto 96-well culture plates, with five multiple wells allocated to each group, and 5000 cells per well. The CCK-8 kit (#KGA9310-1000, Nanjing KeyGen Biotech. Inc., Nanjing, China) was used to examine the cells at 0 h, 24 h, 48 h, and 72 h after they were incubated in an incubator with 37 °C and 5% CO₂.

The 24-well Transwell chamber (Corning, Inc., Cornning, NY, USA) was set up and left at 4 °C for the whole night. Transwell insert was then seeded with a 200 µL cell solution comprising 100,000 cells/mL. The lower chamber was then filled with a culture medium (700 µL) containing 10% Fetal Bovine Serum (FBS). After 24 h of culture, cell fixation was performed using 4% paraformaldehyde at room temperature for 20 minutes, followed by staining with 0.5% crystal violet dye for 5 minutes. The cell count was recorded thereafter.

2.8 Flow Cytometric Analysis of Apoptosis

After being harvested, Hela cells were suspended in a binding buffer. The cells were then stained in accordance with the manufacturer’s instructions using the Annexin V-APC/PI Apoptosis Detection Kit (Nanjing KeyGen Biotech. Inc., Nanjing, China). A Beckman Cytoflex device was used for the flow cytometry analysis, and CytExpert Software (version 2.0, Beckman Coulter, Inc., Brea, CA, USA) was used to analyze the data.

2.9 Statistical Analysis

R software (version 4.0.3; https://www.r-project.org/) was used for all analysis techniques with the exception of internet tools. Tumor and normal sample differential expression was computed using the Wilcoxon rank-sum test. The Spearman and Pearson correlation approach was used to conduct correlation analysis. For the analysis of cell experiment data, GraphPad Prism for Windows (version 9.0.0, GraphPad Software, Inc., San Diego, CA, USA) was used. Three biological replicates of each experiment were conducted and the standard deviation is used to characterize the degree to which the data deviates from the mean. The Student’s t-test was used to determine statistical significance, with p-values of less than 0.05 being regarded as significant. The following were used to indicate the significance levels: *p < 0.05, **p < 0.01, ***p < 0.001.

3. Results

3.1 BZW2 is Upregulated in Multiple Cancer Types in Pan-Cancer

We initially examined the expression of BZW2 in human normal tissues and observed higher levels of BZW2 expression in tissues such as bone marrow, muscle, and heart (Supplementary Fig. 1A). High expression of BZW2 was found in cancer cell lines including stomach adenocarcinoma (STAD) and skin cutaneous melanoma (SKCM) after analysis of the expression patterns of tumor cell lines (Supplementary Fig. 1B). The TCGA data further confirmed elevated levels of BZW2 in tumor tissues
such as rectum adenocarcinoma (READ), colon adenocarcinoma (COAD), and esophageal carcinoma (ESCA) (Supplementary Fig. 1C). Additionally, we observed higher expression of BZW2 in myeloid dendritic cells (Supplementary Fig. 1D,E). Upon merging GTEx and TCGA samples, we observed significant upregulation of BZW2 expression in over 70% of tumor types, including breast invasive carcinoma (BRCA), CESC, lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), brain lower grade glioma (LGG), and thymoma (THYM) (Fig. 1A). BZW2 was significantly upregulated in a number of tumor tissues when compared to paired normal neighboring tissues in the TCGA pan-cancer dataset (Supplementary Fig. 2A–P). We also studied BZW2 expression in four GEO datasets, which revealed that BZW2 expression was significantly higher in cervical cancer (Fig. 1B), lung cancer (Fig. 1C), and endometrial cancer (Fig. 1D) compared with normal tissues. Additionally, we observed high BZW2 expression in metastatic breast cancer (Fig. 1E). BZW2 was substantially increased at the protein expression level in ten different cancer types according to the Clinical Proteomic Tumor Analysis Consortium database. These cancers include breast cancer, colon cancer, ovarian serous cystadenocarcinoma (OV), clear cell renal cell carcinoma (ccRCC), uterine corpus endometrial carcinoma (UCEC), lung cancer, PAAD, and head and neck squamous cell carcinoma (HNSC), glioblastoma multiforme (GBM) and liver cancer (Fig. 1F). Additional immunohistochemistry investigation confirmed that BZW2 is highly expressed on the protein level in a variety of malignancies (Supplementary Fig. 3). These results indicate that BZW2 is upregulated in multiple cancer types, suggesting its potential role in cancer initiation and progression.

3.2 BZW2 is Regulated by Copy Number Amplification and DNA Methylation

We examined BZW2’s SNV and CNV as well as alterations in DNA methylation in the BZW2 promoter region to identify the mechanism causing elevated BZW2 expression. The SNV of BZW2 were primarily missense mutations, with UCEC (n = 175, 3.4%) exhibiting the highest SNV rate (Supplementary Fig. 4A). Furthermore, we observed a higher frequency of copy number amplifications of varying degrees in most cancer types as compared to copy number deletions (Fig. 2A). Multiple cancer types also showed a substantial positive connection between BZW2 mRNA expression and CNV (Supplementary Fig. 4B). The four most relevant cancer types were ESCA (r = 0.568, Supplementary Fig. 4C), HNSC (r = 0.498, Supplementary Fig. 4D), sarcoma (SARC) (r = 0.517, Supplementary Fig. 4E), and READ (r = 0.514, Supplementary Fig. 4F).

At the epigenetic level, we observed significant hypomethylation levels in tumor tissues in more probes (including cg25778479 in the BZW2 body) than in normal tissues (Supplementary Fig. 5A). The results of correlation analysis showed that mRNA expression in the majority of tumor types, including BRCA, CESC, and lung squamous cell carcinoma (LUSC), was strongly negatively linked with the methylation levels of various locations in the BZW2 promoter region and BZW2 body (Fig. 2B). Notably, in cg25778479 and cg22294755 in one-third of cancer types, we found a substantial negative connection between BZW2 mRNA expression and methylation levels (Supplementary Fig. 5B,C). TMB and MSI are key factors in clinical immunotherapy. Our analysis revealed a significant positive correlation between BZW2 expression and TMB in COAD, THYM, lung adenocarcinoma (LUAD), STAD, pheochromocytoma and paraganglioma (PCPG), SARC, and prostate adenocarcinoma (PRAD) (Supplementary Fig. 5D). Additionally, Testicular germ cell tumors (TGCT), THYM, STAD, OV, and other cancers showed a significant positive correlation with MSI (Supplementary Fig. 5E). Moreover, we investigated the relationship between BZW2 mRNA expression and TP53 mutations and discovered a consistent positive link in a variety of malignancies, including BRCA, COAD, HNSC, liver hepatocellular carcinoma (LIHC), LUAD, PAAD, PRAD, and UCEC (Supplementary Fig. 5F). These findings together shed light on the regulatory mechanisms by which BZW2’s DNA copy number amplification and DNA demethylation encourage the upregulation of its mRNA in different cancer types, which may be essential for the development and spread of cancer.

3.3 BZW2 Shapes Non-Inflamed Tumor Microenvironment in Multiple Cancer Types

Conducting a comprehensive pan-cancer analysis to elucidate the immunological effects of BZW2 is vital for identifying cancer types that might benefit from anti-BZW2 immunotherapy. The expression of BZW2 mRNA was shown to be highly correlated with immunological subtypes in various forms of cancer. Specifically, BZW2 exhibited enhanced expression in the C1 subtype (associated with wound healing) of most cancers, including bladder urothelial carcinoma (BLCA), COAD, and LIHC, while it showed lower expression in C3 (associated with inflammation) (Supplementary Fig. 6). Furthermore, BZW2 showed noteworthy negative relationships with the ImmuneScore, EstimateScore, and StromalScore in a variety of cancer types, such as CESC and STAD (Fig. 3A). Besides, we observed significant positive correlations between BZW2 and mismatch-related signatures across almost all cancer types, while significant negative correlations were observed with immune-related signatures in most cancers (Supplementary Fig. 7A). These results point to a possible involvement of BZW2 in the development of different types of cancers.
BZW2 expression pattern in pan-cancer. (A) Basic leucine zipper and W2 domains 2 (BZW2) differential expression throughout the cancer spectrum in normal and tumor tissues (The Cancer Genome Atlas (TCGA) + Genotype-Tissue Expression (GTEx)). Using the Gene Expression Omnibus (GEO) dataset, the differential expression of BZW2 in tumor and normal tissues was examined, including (B) Cervical cancer (GSE9750). (C) Lung cancer (GSE19804). (D) Endometrial cancer (GSE17025). (E) Metastatic breast cancer (GSE43837). (F) Pan-cancer analysis of differential expression of BZW2 protein levels. *p < 0.05, **p < 0.01, ***p < 0.001. TPM, Transcripts per million; UCEC, Uterine Corpus Endometrial Carcinoma; PAAD, Pancreatic Adenocarcinoma.

Based on the xCell method, immune cell infiltration study demonstrated a strong positive link in several cancer types between BZW2 and common lymphoid progenitor, T cell CD4+ Th2. (Fig. 3B–D). On the other hand, BZW2 showed varying degrees of negative correlation with microenvironment scores and other immune cell infiltration (Fig. 3E). An analogous examination utilizing the ssGSEA algorithm disclosed a negative correlation between BZW2 and diverse immune cell infiltrates in several sorts of malignancy (Supplementary Fig. 7B). Besides, we observed mutually exclusive expression of BZW2 with several immune checkpoints in over half of the cancer types. This immunosuppressive effect is particularly evident in TGCT, SKCM, and LUSC (Fig. 3F). Additionally, the TIMER2 web server (http://timer.cistrome.org/) was utilized to examine the relationship between BZW2 and the invasion of four kinds of immune-suppressive cells. The findings showed a strong positive connection between BZW2 and the infiltration of myeloid-derived suppressor cells (MD-SCs) in several cancer types (Supplementary Fig. 7D). Also, we gathered data on 122 immune modulators from the work of Charoentong et al. [27], including MHC, receptors,
chemokines, and immune stimulators, and assessed their relationships with BZW2. We found a negative correlation of BZW2 with most immunomodulators in pan-cancer, and this negative correlation was particularly pronounced in MHC (Supplementary Fig. 8). These findings indicate that high BZW2 expression may downregulate antigen presentation and processing capabilities. Moreover, several chemokine receptors were also observed to be significantly negatively correlated with BZW2, including CXCR3, which mediates the chemotaxis and activation of T lymphocytes and natural killer cells, and CXCR5, which regulates the chemotaxis and activation of B cells. However, the multifaceted functions of the chemokine system warrant further investigation, and these results alone are insufficient to elucidate the overall immune role of BZW2 in the tumor microenvironment.

Chemokines and their receptors are immune regulatory elements whose actions are directly reflected in the activity of the cancer immune cycle. Our analysis reveals a significant negative correlation between BZW2 and various steps of the cancer immune cycle, including antigen release (Step 1) and priming and activation (Step 3), in cancers, including BRCA, COAD, ESCA and other cancers (Supplementary Fig. 9). Additionally, trafficking of immune cells to tumors, such as CD8+ T cell recruiting, Macrophage recruiting, Th1 cell recruiting, NK cell recruiting, and Dendritic cell recruiting (Step 4), is also significantly negatively correlated with BZW2 in several cancer types, including BRCA, SKCM, TGCT, and THCA. Reduced activity of these steps may reduce the infiltration of effector tumor-infiltrating immune cells in the tumor microenvironment. Notably, a significant negative correla-
tion was observed between the infiltration of immune cells into tumors (Step 5) and BZW2 in more than 20 cancer types (Supplementary Fig. 9). These findings underscore BZW2’s role in shaping a non-inflammatory immunosuppressive tumor microenvironment in various cancers.

Considering the immunosuppressive role of BZW2 in tumors, we evaluated its responsiveness to predict immune checkpoint blockade (ICB) treatment. Higher TIDE scores indicate worse ICB efficacy and shorter post-treatment survival. Notably, in GBM, kidney renal clear cell carcinoma (KIRC), LGG, LIHC, LUAD, PCPG, READ, SARC, and TGCT, we found higher TIDE scores in the BZW2 high-expression group. This suggests that the BZW2 low-expression group has superior ICB efficacy and longer post-treatment survival (Supplementary Fig. 10A–I, Supplementary Table 2). What’s more, we employed the IPS to assess the response to immunotherapy. Stronger immunogenicity and better immunotherapy benefit are correlated with higher IPS values. Our findings demonstrated that the BZW2 low-expression group of GBM, KIRC, and LUAD patients exhibited stronger immunogenicity when treated with PD1, CTLA4, and combination therapy (Supplementary Fig. 10J–L).

3.4 BZW2 is Associated with Tumor Stemness and Drug Sensitivity

Cancer stem cells have the potential to self-renew and differentiate in several directions, and they may continually make new tumor cells, which is critical for tumor formation and progression. We evaluated the correlation between BZW2 expression and two tumor stemness indices (EREG, EXPs and RNAss). The stemness score and BZW2 expression in various malignancies showed a strong positive connection, according to our data (Fig. 4A–C). Additionally, we also evaluated the stemness index of pan-cancer samples using the OCLR algorithm and found that the BZW2 high expression group exhibited higher stemness scores in multiple cancers (Fig. 4D). These findings suggested that elevated BZW2 expression may promote the stemness characteristics of cancer cells, thus affecting autophagy activity.

We also assessed the correlation between the BZW2 gene and 198 drugs, revealing significant negative correlations between BZW2 and 28 drugs, such as Gefitinib and Afatinib. Subsequent analysis indicated that these drugs with significant correlations predominantly targeted the EGFR pathway (Supplementary Fig. 11), highlighting the potential significance of the BZW2 gene in regulating this pathway.

3.5 BZW2 is Associated with Multiple Cancer-Related Pathways

We performed a GSVA enrichment analysis to gather knowledge about the possible roles and processes of BZW2 in pan-cancer. A number of cancer-related pathways, such as MYC targets (Fig. 5B), G2/M checkpoint, mTORC1 signaling (Fig. 5C), E2F targets, PI3K AKT mTOR signaling, and DNA repair, were considerably enriched, as Fig. 5A illustrates. Additionally, we also observed a significant negative correlation between BZW2 and KRAS signaling dn (Fig. 5D) and inflammatory response pathways (Fig. 5E) in some cancers. Furthermore, we found that BZW2 and immune-inflammatory pathways significantly correlated negatively in more than half of the cancer types (Fig. 5F). Correlation analysis also uncovered a significantly positive correlation between BZW2 expression and multiple oncoproteins (Fig. 5G).

3.6 BZW2 is an Independent Prognostic Factor in CESC

The expression of BZW2 mRNA is strongly linked to a poor prognosis in a variety of cancer types. In particular, worse OS, DSS, and PFI were substantially correlated with higher BZW2 expression in adenocortical carcinoma (ACC), CESC, LIHC, LUAD, PAAD, and SARC. Furthermore, poorer OS in HNSC and thyroid cancer (THCA), worse DSS in kidney chromophobe cell carcinoma (KICH), KIRC, and PRAD, and worse PFI in HNSC, KICH, and KIRC were all significantly correlated with increased BZW2 expression (Fig. 6A, Supplementary Fig. 12A). BZW2 has been discovered as a prognostic factor for a variety of malignancies, including CESC (Fig. 6A–E). Diagnostic ROC curve analysis revealed that the area under the curve (AUC) for CESC was 0.956, with the AUC of BZW2 effectively predicting the overall recurrence rate at 1, 2, and 3 years (0.712, 0.646, and 0.666, respectively) (Fig. 6F,G). BZW2 was found to be an independent predictive factor for CESC in univariate and multivariate Cox regression models (Fig. 6H).

We looked at the relationship between BZW2 and CESC clinical characteristics since there is a strong link between BZW2 and the clinical prognosis of CESC. Our findings revealed significant correlations between BZW2 and both age and grade stage in CESC (Supplementary Fig. 12B–D). Notably, as the malignancy of CESC increased, there was a gradual increase in the expression level of BZW2, indicating its close association with CESC development.

3.7 BZW2 Regulates Cervical Cancer Cell Proliferation and Migration

Expression levels of BZW2 in CESC cell lines were analyzed using CCLE data, revealing higher BZW2 expression in Hela cells (Fig. 7A). Hela cells were therefore chosen for further studies. Hela cells were effectively transfected with two BZW2 siRNA knockout vectors. The transfected group’s effective suppression of mRNA and protein expression in comparison to the control group (siRNC) was shown by RT-PCR and western blot analysis (Fig. 7B,C). The cell viability post-transfection with siRNC, siRNA1, and siRNA2 was assessed using the CCK8 kit, revealing a
Fig. 3. Correlation of BZW2 and immune signatures in pan-cancer. (A) The ESTIMATE algorithm evaluated the relationship between BZW2 and tumor microenvironment. (B) The relationship between BZW2 and immune cell infiltration is evaluated by the xCell algorithm. (C) The infiltration of common lymphoid progenitor cells was positively linked with BZW2. (D) The infiltration of T cell CD4+ Th2 cells was positively linked with BZW2. (E) BZW2 was negatively correlated with microenvironment score. (F) Correlation between immune checkpoints and BZW2 in pan-cancer.

significant reduction in cell proliferation ability after 24 h, 48 h, and 72 h of BZW2 knockout (Fig. 7D). The cell apoptosis experiment further revealed that siRNC had an average apoptosis rate of 8.4%, but siRNA1 and siRNA2 had rates of 33.2% and 30.1%, respectively (Fig. 7E,F). Additionally, the Transwell experiment showed that BZW2 deletion significantly reduced the capacity of Hela cells to migrate (Fig. 7G,H). All of these findings point to the critical function BZW2 plays in controlling the migration and proliferation of cervical cancer cells.

4. Discussion

BZW2 is a well-established tumor-related gene with significant implications in the study of tumor biology [28]. It has been associated with various cancer types, such as osteosarcoma [29], colorectal cancer [30,31], lung adenocarcinoma [32] and fibrosarcoma [33]. Despite its acknowledged importance, a thorough investigation of all cancer types is currently required in order to evaluate BZW2’s differential expression, immunological markers, and epigenetic alterations in tumor heterogeneity. Here, we assessed
Fig. 4. Correlation between BZW2 and cancer stemness. (A) BZW2 was positively correlated with the stemness score of multiple cancers. (B) Relationship between BZW2 and epigenetically regulated RNA expression-based (EREG.EXPss). (C) Relationship between BZW2 and RNA expression-based (RNAss). (D) One-class logistic regression machine learning algorithm (OCLR) evaluates stemness score. * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \). EREG.EXPss, Epigenetically regulated RNA expression-based; RNAss, RNA stemness scores.

The differential expression of BZW2 by the first pan-cancer investigation. Our findings demonstrate that BZW2 expression is markedly elevated in the majority of malignancies, both in terms of mRNA and protein. The mRNA expression of BZW2 is modulated by CNV and methylation levels. A previous study by Huang et al. [34] demonstrated that METTL3 facilitates m6A methylation of BZW2, contributing to the progression of multiple myeloma. Our investigation, which made use of methylation data from the TCGA database, demonstrated the epigenetic changes of BZW2 in a range of malignancies. Alterations in CNVs have the ability to influence signaling system activity and regulate the aberrant expression of many genes [35]. We found a significant negative correlation between BZW2 mRNA expression and its methylation level, while a significant positive correlation existed with CNV. Notably, this correlation appears to be cancer-type-dependent, emphasizing the role of epigenetic changes in mediating BZW2 mRNA expression, which could be critical in the etiology and progression of cancer. The substantial copy number amplification of BZW2 in most cancers could promote cancer progression. Importantly, these epigenetic modifications, involving aberrant methylation and CNVs of BZW2, are associated with poor prognosis in various cancers, highlighting their potential clinical impact on cancer outcomes. The TP53 gene, a pivotal tumor suppressor gene, is closely linked to the onset and progression of various cancers [36]. Our analysis revealed a higher frequency of TP53 mutations in the
**Fig. 5. Correlation between BZW2 and cancer-related pathways.** (A) Gene Set Variation Analysis (GSVA) enrichment analysis assesses the relevance of BZW2 and pathways. (B) Correlation between MYC TARGETS V1 and BZW2. (C) Correlation between MTORC1 SIGNALING and BZW2. (D) Correlation between KRAS SIGNALING DN and BZW2. (E) Correlation between INFLAMMATORY RESPONSE and BZW2. (F) Correlation between BZW2 and immune-inflammatory pathways. (G) Correlation between BZW2 and oncogenes.

*Fig. 5.*

BZW2 high-expression group across multiple cancers. This result highlights the association between BZW2 expression and *TP53* mutations, shedding light on how *TP53* gene mutations may influence tumor initiation and progression.

Dynamic changes in the tumor microenvironment and the degree of infiltration of different immune cells determine the progression of the tumor and the degree of response to immunotherapy [37]. The results of our study showed a substantial negative association with immune-associated aspects and a strong positive relationship between the BZW2 gene expression and features related to mismatch repair. This suggests that BZW2 may affect the mismatch repair mechanism, thus inhibiting tumor genome instability, but at the same time, it inhibits the immune system’s response, leading to tumor escape and progression. The findings of the examination of immune cell infiltration further demonstrate BZW2’s immunosuppressive function in a variety of malignancies. Immunosuppressive properties of MDSC immune cells are well recognized [38]. They can lessen the immune system’s capacity to combat cancer cells by suppressing the function of other immune cells. We found a considerable positive correlation between the infiltration of MDSC immune cells and the BZW2 gene in many cancers. This implies that BZW2 may increase the immunosuppressive effect by promoting the infiltration of immune cells known as MDSC, which in turn stimulates the growth of cancer. Additionally, we discovered a substantial negative correlation between BZW2 and a number of immune regulatory factors as well as different stages of the cancer immune cycle. This finding implies that BZW2 may depress the immune system by comprehensively downregulating the expression of many immunomodulators, which would lower the immune system’s action against cancer. This leads to a decrease in the recruitment of effector immune cells and the promotion of a non-inflamed tumor microenvironment. Our results indicate that BZW2 promotes cancer progression in multiple cancers by shaping a non-inflamed immunosuppressive microenvironment.

The stemness score is a valuable indicator, often associated with tumor malignancy and treatment response. A high stemness score indicates that tumor cells possess robust stemness characteristics, rendering them more resistant to chemotherapy and radiotherapy [39]. Our analysis has revealed that the BZW2 low-expression group exhib-
Fig. 6. Correlation between *BZW2* and pan-cancer prognosis. (A) Univariable cox regression analysis of *BZW2*. (B) Association between *BZW2* and overall survival in cervical cancer. (C) Association between *BZW2* and disease specific survival in cervical cancer. (D) Association between *BZW2* and progression free interval in cervical cancer. (E) Association between *BZW2* and disease free interval in cervical cancer. (F) Analysis of the diagnostic efficacy of *BZW2* in cervical cancer. (G) TimeROC (receiver operating characteristic) analysis of *BZW2* in cervical cancer. (H) Univariate and multivariate analysis results of *BZW2* in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC).

...lower stemness scores across multiple cancers, suggesting that the *BZW2* gene plays a significant role in regulating the stemness characteristics of tumor cells. Further research is needed to uncover the mechanisms underlying tumor development and to develop new treatment strategies. Furthermore, our drug sensitivity analysis has identified a significant negative correlation between *BZW2* and multiple EGFR pathway-related drugs. This finding implies that tumor cells expressing high levels of the *BZW2* gene are less sensitive to drugs targeting the EGFR pathway. Therefore, the *BZW2* gene likely plays a role in the regulation of the EGFR pathway, affecting the responsiveness of tumor cells to related drugs. Also, a strong correlation between *BZW2* and various prognostic characteristics of CESC was found by survival analysis. *BZW2* was validated as an independent predictive factor for CESC in subsequent univariate and multivariate studies. These results demonstrate the significance of *BZW2* in carcinogenesis and prognosis as a whole. Furthermore, GSVA enrichment analysis demonstrated a substantial positive link between the *BZW2* gene and the myc targets pathway, indicating that *BZW2* may have potential functions in cell proliferation, apoptosis, and cell cycle regulation. To verify this, we conducted cell experiments, which confirmed that *BZW2* knockdown significantly reduces proliferation, migration, and apoptosis of CESC Hela cell lines.

In conclusion, our research is the first thorough examination of the *BZW2* gene in a variety of cancer forms. Our work revealed that *BZW2* exhibits high expression in multiple tumor types and serves as an independent prognostic factor, particularly in CESC. Our study extensively examines the epigenetic modifications and immunological features of *BZW2* in pan-cancer. Moreover, experiments involving *BZW2* knockout demonstrate its impact on the proliferation, migration, and apoptosis of CESC cells. These findings shed light on the potential functional mechanisms and clinical prognostic characteristics of *BZW2* in pan-cancer and offer valuable insights for future immunotherapy research.
Fig. 7. **BZW2** knockdown’s impact on the CESC cell line Hela, a total of 3 biological replicates were performed for each set of experiments. (A) The Cancer Cell Line Encyclopedia (CCLE) dataset examined **BZW2** expression in several CESC cell lines. (B) Verification of **BZW2** knockdown effectiveness in Hela cells using real-time polymerase chain reaction (RT-PCR). (C) By using Western blot, the knockdown effectiveness of **BZW2** in Hela cells was confirmed. (D) Using the Cell Counting Kit-8 (CCK8) test, examine how **BZW2** knocked affects cell proliferation. (E) The rate of apoptosis in Hela cells with cervical cancer was increased by **BZW2** knocked. (F) The percentage of apoptotic cells in the three groups. (G) **BZW2** deletion significantly reduced the capacity of Hela cells to migrate. (H) The number of migrated cells in the three groups. *p < 0.05, **p < 0.01, ***p < 0.001. The Transwell experiment results are generated under a 40× magnification, and the scale bar is 100 μm.

5. Conclusions

In summary, based on a global pan-cancer perspective, we found that **BZW2** promotes cancer progression by forming a non-inflammatory immunosuppressive tumor microenvironment. In addition, **BZW2** can also significantly affect the proliferation, migration and apoptosis of CESC cells. Our findings may help understand the association between **BZW2** and cancer progression and provide ideas for immunotherapy research.
Availability of Data and Materials
The data that support the findings of this study are available from the corresponding author on reasonable request.

Author Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by CL, QL, LL, SS and XL. QL and CL jointly completed the cell experiments. The first draft of the manuscript was written by CL and all authors commented on previous versions of the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate
Not applicable.

Acknowledgment
We thank Bullet Edits Limited for the linguistic editing and proofreading of the manuscript.

Funding
This study was funded by scientific research project of Sichuan Maternal and Child Health Association (No. 22FXZD04) and general Project of Scientific Research Project of Jinniu District Medical Association, Chengdu City, Sichuan Province (JNKY2021-52).

Conflict of Interest
The authors declare no conflict of interest.

Supplementary Material
Supplementary material associated with this article can be found, in the online version, at https://doi.org/10.31083/j.fbl2903097.

References


